MAVOGLURANT
Total Payments
$28,548
Transactions
3
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $28,548 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26,673 | 2 | 93.4% |
| Consulting Fee | $1,875 | 1 | 6.6% |
Payments by Type
Research
$26,673
2 transactions
General
$1,875
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AFQ056 IN ADOLESCENT PATIENTS WITH FRAGILE X SYNDROME | Novartis Pharmaceuticals Corporation | $16,255 | 0 |
| AN OPEN LABEL STUDY TO EVALUATE THE LONG TERM SAFETY TOLERABILITY AND EFFICACY OF AFQ056 IN ADULT PATIENTS WITH FRAGILE X SYNDROME | Novartis Pharmaceuticals Corporation | $10,418 | 0 |
Top Doctors Receiving Payments for MAVOGLURANT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $26,673 | 2 |
| , MD | Addiction Medicine | Houston, TX | $1,875 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $28,548
- Total Doctors 1
- Transactions 3
About MAVOGLURANT
MAVOGLURANT is a drug associated with $28,548 in payments to 1 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2017. In 2017, $28,548 was paid across 3 transactions to 1 doctors.
The most common payment nature for MAVOGLURANT is "Unspecified" ($26,673, 93.4% of total).
MAVOGLURANT is associated with 2 research studies, including "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AFQ056 IN ADOLESCENT PATIENTS WITH FRAGILE X SYNDROME" ($16,255).